Role of 5 alpha-reductase inhibitors in the management of prostate cancer

(2417) Views  (656) Full article downloads

Authors: Steven J Hudak, Javier Hernandez, Ian M Thompson

Published Date February 2006 Volume 2006:1(4) Pages 425 - 431

DOI: http://dx.doi.org/10.2147/CIA.S

Steven J Hudak¹, Javier Hernandez¹, Ian M Thompson²
 

¹Urology Service, Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX, USA; ²Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Abstract: Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient. 5 alphareductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized clinical trial to decrease the risk of prostate cancer with a reduction of almost 25%. Additionally, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that finasteride improves the performance characteristics of prostate-specific antigen (PSA) blood test as a screening tool for prostate cancer, for both cancer detection as well as for detection of high risk disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding the toxicity of medical and surgical castration.

Keywords: prostate cancer, 5-α-reductase inhibitors, finasteride, dutasteride, chemoprevention